RDInvesting Provides Investors with Free In-Depth Equity Reports on GPRE, NXPI, SCLN and SNTA
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Green Plains Renewable Energy Inc. (NASDAQ: GPRE) shares spiked 3.26 percent to close at $15.84 a share Tuesday. The stock traded between $15.16 and $16.07 on volume of 849,838 shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” and currently have a price target of $16.10 on the stock. Shares of Green Plains Renewable Energy have gained over 100.0 percent year-to-date.
Find out more about Green Plains Renewable Energy including full access to the free equity report at:
www.RDInvesting.com/GPRE
NXP Semiconductors NV (NASDAQ: NXPI) shares increased 1.37 percent to close at $33.31 a share Tuesday. The stock traded between $32.78 and $33.32 on volume of 1.34 million shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” and currently have a price target of $35.00 on the stock. Shares of NXP Semiconductors have gained over 26.0 percent year-to-date.
Find out more about NXP Semiconductors including full access to the free equity report at:
www.RDInvesting.com/NXPI
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) shares jumped 4.94 percent to close at $5.95 a share Tuesday. The stock traded between $5.91 and $6.18 on volume of 612,341 shares traded. Analysts at Goldman have recently downgraded the company’s rating to “neutral” from “buy”. Shares of SciClone Pharmaceuticals have gained approximately 38.0 percent year-to-date.
Find out more about SciClone Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/SCLN
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares increased 2.76 percent to close at $5.59 a share Tuesday. The stock traded between $5.52 and $5.84 on volume of 2.06 million shares traded. Analysts at JMP Securities have recently upgraded the company’s rating to “outperform” and currently have a price target of $11.00 on the stock. Shares of Synta Pharmaceuticals have fallen approximately 38.0 percent year-to-date.
Find out more about Synta Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/SNTA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com